• Genomma Lab posted Q2 2026 net sales of MXN 4.4 billion, down 6% year over year.
• Net income rose 5.5% to MXN 374.49 million, helped by lower financial expenses and smaller FX losses.
• EBITDA fell 13.9% to MXN 958.6 million, with margin down 2 percentage points to 21.8%.
• Mexico net sales slipped 4.4% to MXN 2.07 billion, while U.S. dropped 27.7% to MXN 333.7 million.
• CEO Marco Sparvieri flagged early-July sell-out growth in key accounts, led by the Suerox Mineral launch, as traction builds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genomma Lab International SAB de CV published the original content used to generate this news brief on July 22, 2026, and is solely responsible for the information contained therein.